Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl(R)). Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 and 28 followed by 4-weekly injections until tumor progression. No objective responses were observed. Eleven out of 68 evaluable patients (16%) had stable disease. The median progression-free survival was 5 months in patients with disease stabilization and 2 months for all evaluable patients. The median survival for patients with disease stabilization was 17 months, whereas for all patients it was 4 months. The treatment was well tolerated; the only reported adverse events were incidental hot flushes. This study showed that the LHRH agonist Triptorelin has only modest efficacy in patients pretreated with platinum-containing chemotherapy. [(C) 2001 Lippincott Williams & Wilkins.].
Duffaud, F ; van der Burg, MEL ; Namer, M ; Vergote, Ignace ; Willemse, PHB ; et. al. D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC gynaecological cancer co-operative group study. In: Anti-Cancer Drugs : international journal on anti-cancer agents, Vol. 12, no. 2, p. 159-162 (2001)